The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 26, 2019

Filed:

Sep. 18, 2014
Applicant:

Tufts Medical Center, Inc., Boston, MA (US);

Inventors:

Navin K. Kapur, Hanover, MA (US);

Richard H. Karas, Franklin, MA (US);

Assignee:

Tufts Medical Center, Inc., Boston, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/28 (2006.01); A61K 38/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 38/177 (2013.01); A61K 38/1793 (2013.01); A61K 38/2066 (2013.01); A61K 38/21 (2013.01); A61K 38/28 (2013.01); A61K 38/4886 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12Y 304/2408 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

Endoglin has been identified to play a functional role as a regulator of TGFβ1 signaling, particular in TGFβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGFβ1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.


Find Patent Forward Citations

Loading…